KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest & Investment Income: 2009-2024

Historic Interest & Investment Income for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Dec 2024 value amounting to $598.1 million.

  • Vertex Pharmaceuticals' Interest & Investment Income fell 4.92% to $125.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $497.2 million, marking a year-over-year decrease of 23.44%. This contributed to the annual value of $598.1 million for FY2024, which is 2.70% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Interest & Investment Income stood at $598.1 million for FY2024, which was down 2.70% from $614.7 million recorded in FY2023.
  • Vertex Pharmaceuticals' 5-year Interest & Investment Income high stood at $614.7 million for FY2023, and its period low was $4.9 million during FY2021.
  • Over the past 3 years, Vertex Pharmaceuticals' median Interest & Investment Income value was $598.1 million (recorded in 2024), while the average stood at $452.5 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Interest & Investment Income slumped by 77.93% in 2021 and then spiked by 2,851.02% in 2022.
  • Over the past 5 years, Vertex Pharmaceuticals' Interest & Investment Income (Yearly) stood at $22.2 million in 2020, then slumped by 77.93% to $4.9 million in 2021, then spiked by 2,851.02% to $144.6 million in 2022, then surged by 325.10% to $614.7 million in 2023, then decreased by 2.70% to $598.1 million in 2024.